CREATE Medicines to Present In Vivo CAR-T Preclinical Data at APLAR 2026 Congress
CREATE Medicines, Inc. has announced it will host a pre-congress workshop and present oral abstract data at the Asia-Pacific League of Associations for Rheumatology (APLAR) 2026 Congress in Seoul. The company plans to showcase preclinical mouse and non-human primate data regarding its lead program, CRT-402, which demonstrates complete B cell depletion in lymph nodes, spleen, and bone marrow using low doses of in vivo CAR-T technology. CRT-402 utilizes a targeted mRNA-LNP platform designed to reprogram a patient's own T cells directly inside the body. This approach aims to replicate the 'immune reset' achieved by traditional ex vivo CAR-T therapies but without the need for external cell manufacturing or lymphodepleting chemotherapy. The program is currently in a Phase 1/2 clinical study in Australia targeting lupus, systemic sclerosis, and myositis.
Topics: autoimmune disease biotechnology workshop clinical trial data in vivo CAR-T